Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2024) 144 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2024-208505

Published: 2024

Journal Articles

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Alexey V. Danilov, Vi Lam, Bria Thurlow, Stephen E. Spurgeon, Byung Park, Kirsten Orand, Adam S Kittai

Blood (2021) 138 (Supplement 1): 2643.

https://doi.org/10.1182/blood-2021-146348

Published: 2021

Journal Articles

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

Max J. Gordon, Andy Kaempf, Emelie Rotbain, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Michael Choi, Jonathon B. Cohen, Deborah M. Stephens, Dan O. Persky, Krish Patel, Mazyar Shadman, Byung Park, Carsten Utoft Niemann, Alexey V. Danilov

Blood (2021) 138 (Supplement 1): 2637.

https://doi.org/10.1182/blood-2021-148253

Published: 2021

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

Max J. Gordon, MD, Andy Kaempf, MS, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, BS, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MDMPH, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-136808

Published: 2020

Journal Articles

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

DR. Brian Koffman, John M. Pagel, MD PhD DSc, Andy Kaempf, Byung Park, PhD, Liza Avruch, Christopher Lee, PhD MS, Babak Movassaghi, PhD MBA, John C. Byrd, MD, Alan Skarbnik, MD, Matthew S. Davids, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4716.

https://doi.org/10.1182/blood-2019-123579

Published: 2019

Journal Articles

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

Max J. Gordon, MD, Andy Kaempf, Andrea Sitlinger, MD, Tareq Salous, Hamood Alqahtani, MBBS, Michael C. Churnetski, Paul Wisniewski, Xavier Issac Rivera, BS, Krish Patel, MD, Daniel O. Persky, MD, Jonathon B. Cohen, MDMS, Michael Y. Choi, MD, Brian T. Hill, MD, Mazyar Shadman, MD, Deborah M. Stephens, DO, Danielle M. Brander, MD, Byung Park, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4286.

https://doi.org/10.1182/blood-2019-124631

Published: 2019

Journal Articles

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Adam S. Kittai, MD, Scott R Best, BS, Bria Thurlow, BSc, Basak Gokcora, Andrzej Stadnik, MPH, BS, Renee MacKinnon, Taylor Hashiguchi Rowland, BS, Daniel O. Persky, MD, Byung Park, PhD, Stephen E Spurgeon, MD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4295.

https://doi.org/10.1182/blood-2019-123586

Published: 2019

Journal Articles

Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia

Max J. Gordon, MD, Michael C Churnetski, BS, Hamood Alqahtani, MBBS, Xavier Issac Rivera, BS, Adam Kittai, MD, Nur Bruss, BS, Sheila Hoff, BSN, Michael Y. Choi, MD, Jonathon B. Cohen, MD MS, Daniel Persky, MD, Byung Park, PhD, Alexey V Danilov, MD PhD

Blood (2018) 132 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2018-99-113917

Published: 2018

Journal Articles

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Tibor Kovacsovics, Byung Park, Brandon Hayes-Lattin, Jose F. Leis, Peter T. Curtin, Gabrielle Meyers, Elliot Epner, Richard T. Maziarz

Blood (2007) 110 (11): 1988.

https://doi.org/10.1182/blood.V110.11.1988.1988

Published: 2007

Journal Articles

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

Grover C. Bagby, MD, Shannon McWeeney, PhD, Jane Yates, Byung Park, PhD, R. Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD, D. Wade Clapp, MD

Blood (2006) 108 (11): 2636.

https://doi.org/10.1182/blood.V108.11.2636.2636

Published: 2006

Journal Articles

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian J. Druker, Michael W. Deininger

Blood (2005) 106 (6): 2128–2137.

https://doi.org/10.1182/blood-2005-03-1036

Published: 2005

Journal Articles

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Grover Bagby, MD, Jane Yates, Shannon McWeeney, PhD, Byung Park, MS, Keaney Rathbun, Daniela Pilonetto, PhD, Richard Harris, MD, John Wagner, MD, Gerard Pals, PhD, See Yan Lau, MS, Christina Harrington, PhD, Motomi Mori, PhD, Ricardo Pasquini, MD

Blood (2004) 104 (11): 3416.

https://doi.org/10.1182/blood.V104.11.3416.3416

Published: 2004

NARROW

Phase 1 Trial Testing the Novel Combination Therapy of Entrectinib and ASTX727 in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia Patients

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study

An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated with Ibrutinib and/or Chemo-Immunotherapy (CIT)

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Impact of Individual Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia

Applying the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) in Myeloablative MUD Transplants Predicts NRM and OS Using a Modified 2-Tier Scoring System.

Comparative Functional Genomic Analysis of Myelodysplasia (MDS) in Fanconi Anemia (FA).

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Clonal Evolution of Fanconi Anemia (FA) Stem Cells Results from Clonal Adaptation and Clonal Selection. A Report from the International Fanconi Anemia Transcriptome Consortium.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only